Summary
Hospira Inc (Hospira), a subsidiary of Pfizer Inc, is a medical device company that offers injectable drugs and infusion technologies. The company offers products such as generic acute-care and oncology injectables, biosimilars, infusion systems, IV sets, IV safety devices, biosimilars, differentiated delivery systems, IV clinical integration and safety software, and medication management products. It provides clinical services, project management, field services, EMR integration and implementation services. Hospira provides contract manufacturing services to proprietary pharmaceutical and biotechnology companies for formulation development, filling and finishing of injectable pharmaceuticals. The company has operations in Brazil, Canada, Mexico, Italy, France, Germany, Spain, South Korea, China, the US, Australia, and others. Hospira is headquartered in Lake Forest, Illinois, the US.
Hospira Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Hospira Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Hospira Inc, Medical Devices Deals, 2011 to YTD 2017 12
Hospira Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Hospira Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 15
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 16
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 18
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 19
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 20
Partnerships 21
Mayne Pharma Enters into Distribution Agreement with IDT Australia 21
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 22
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 24
Licensing Agreements 26
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 26
Clinigen Extends Licensing Agreement with Hospira for Foscavir 27
Orion And Hospira Extend Licensing Agreement For Precedex 28
HedgePath Pharma Enters Into Licensing Agreement With Mayne Pharma 29
Hospira Enters into Licensing Agreement with NovaQuest for Filgrastim 31
Hospira Enters into Licensing Agreement with NovaQuest for Erythropoietin Biosimilar 32
Hospira Enters into Licensing Agreement with NovaQuest for Pegylated Filgrastim 33
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 34
Ligand Pharma Enters Into Licensing Agreement With Hospira 35
Clinigen Enters Into Licensing Agreement With Hospira For Foscavir 36
Kiadis Pharma Enters Into Licensing Agreement With Hospira For ATIR 37
Equity Offering 38
Mayne Pharma to Raise USD444.5 Million in Rights Offering of Shares 38
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 40
HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 42
HedgePath Pharma to Raise USD2.5 Million in Private Placement of Shares and Warrants 43
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 44
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 45
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 46
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 47
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 49
Acquisition 50
Pfizer Acquires Hospira for USD17 Billion 50
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 52
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 53
Metrics Acquires Midlothian Labs From Hi-Tech Pharmacal 55
Hospira Inc - Key Competitors 56
Hospira Inc - Key Employees 57
Hospira Inc - Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Joint Venture 59
Recent Developments 60
Product News 60
Jul 28, 2017: ICU Medical Issues a Voluntary Nationwide Recall of One Lot of 0.9% Sodium Chloride Injection Due to the Presence of Particulate Matter 60
Jun 15, 2017: Hospira Issues a Voluntary Nationwide Recall For 8.4% Sodium Bicarbonate Injection, USP, Neut, QUELICIN and Potassium Phosphates Injection 61
Apr 21, 2017: Hospira Issues a Voluntary Nationwide Recall For One Lot Of 25% Dextrose Injection, USP (Infant) Due To The Presence of Particulate Matter 62
Mar 18, 2016: Hospira Issues a Voluntary Recall for One Lot of Sodium Bicarbonate Injection, USP Due to the Presence of a Particulate 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
List Of Tables
List of Tables
Hospira Inc, Pharmaceuticals & Healthcare, Key Facts 2
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Hospira Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Hospira Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Hospira Inc, Medical Devices Deals, 2011 to YTD 2017 12
Hospira Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 15
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 16
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 18
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 19
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 20
Mayne Pharma Enters into Distribution Agreement with IDT Australia 21
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 22
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 24
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 26
Clinigen Extends Licensing Agreement with Hospira for Foscavir 27
Orion And Hospira Extend Licensing Agreement For Precedex 28
HedgePath Pharma Enters Into Licensing Agreement With Mayne Pharma 29
Hospira Enters into Licensing Agreement with NovaQuest for Filgrastim 31
Hospira Enters into Licensing Agreement with NovaQuest for Erythropoietin Biosimilar 32
Hospira Enters into Licensing Agreement with NovaQuest for Pegylated Filgrastim 33
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 34
Ligand Pharma Enters Into Licensing Agreement With Hospira 35
Clinigen Enters Into Licensing Agreement With Hospira For Foscavir 36
Kiadis Pharma Enters Into Licensing Agreement With Hospira For ATIR 37
Mayne Pharma to Raise USD444.5 Million in Rights Offering of Shares 38
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 40
HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 42
HedgePath Pharma to Raise USD2.5 Million in Private Placement of Shares and Warrants 43
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 44
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 45
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 46
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 47
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 49
Pfizer Acquires Hospira for USD17 Billion 50
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 52
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 53
Metrics Acquires Midlothian Labs From Hi-Tech Pharmacal 55
Hospira Inc, Key Competitors 56
Hospira Inc, Key Employees 57
Hospira Inc, Subsidiaries 58
Hospira Inc, Joint Venture 59
List Of Figures
List of Figures
Hospira Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Hospira Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Hospira Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Hospira Inc, Medical Devices Deals, 2011 to YTD 2017 12
